<unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes such as refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia.   Common adverse reactions include anemia, neutropenia, thrombocytopenia, hepatic coma and elevated serum creatinine, renal failure, and renal tubular acidosis.
Azacytidine
Lafutidine
Decitabine
Trifluridine
Ibacitabine
Vincristine sulfate
Floxuridine
Idoxuridine